People undergoing hemodialysis treatment for kidney failure often experience chronic pain related to their condition, but it ...

The FDA approves Vertex's non-opioid oral pain signal inhibitor, Journavx, for treating adults with moderate-to-severe acute pain. Shares rise.

The following is a summary of “Feasibility of trancutaneous auricular vagus nerve stimulation in Black and Hispanic/Latino people with peripheral neuropathy,” published in the January 2025 issue of ...

The US Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

GP Dr Roger Henderson provides an overview of the chronic complications of diabetes and the key preventive measures ...

In recent weeks, reports have been circulating about severe reactions in people who've taken over-the-counter vitamin B6 ...

The following is a summary of “Correlation between high-sensitivity cardiac troponin levels in diabetic patients’ serum and ...

SLEEP is essential for good health and well-being. It keeps heart health in check, helps you maintain a healthy weight, makes ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...